Skip to main content
. 2012 Oct;11(10):1289–1299. doi: 10.1128/EC.00215-12

Table 2.

Primers used in this study

Purpose, primer Sequencea
qRT-PCR
    ACT1-F 5′-ACGGTGAAGAAGTTGCTGCTTTAGTT-3′
    ACT1-R 5′-CGTCGTCACCGGCAAAA-3′
    18S-F 5′-CACGACGGAGTTTCACAAGA-3′
    18S-R 5′-CGATGGAAGTTTGAGGCAAT-3′
    ERG11-F 5′-CCCCTATTAATTTTGTTTTCCCTAATTTAC-3′
    ERG11-R 5′-CACGTTCTCTTCTCAGTTTAATTTCTTTC-3′
    CDR1-F 5′-ATTCTAAGATGTCGTCGCAAGATG-3′
    CDR1-R 5′-AGTTCTGGCTAAATTCGTAATGTTTTC-3′
    CDR2-F 5′-TAGTCCATTCAACGGCAACAAT-3′
    CDR2-R 5′-CACCCAGTATTTGGCATTGAAA-3′
    BMR1-F 5′-ACATAAATACTTTGCCCATCCAGAA-3′
    BMR1-R 5′-AAGAGTTGGTTTGTAATCGGCTAAA-3′
UPC2 mutant construction
    UPC2-A 5′-GGGCCCGAGATCTTGATGTCATTAG-3′
    UPC2-B 5′-CTCGAGCTATATCTTCAATGAACTG-3′
    UPC2-E 5′-CTCGAGCACCACAGTAACGAATCAC-3′
    UPC2-C 5′-CCGCGGACAGGTCAATACCGCGTAG-3′
    UPC2-D 5′-GAGCTCGTTCCTCTAGTATCACTCTT-3′
UPC2 sequencing
    UPC2seqA 5′-CTGCAGAGAATCACAGTGAAGTTC-3′
    UPC2seqB 5′-CTCAGCCGGTGATTCCTCCA-3′
    UPC2seqC 5′-CGGTCAAACCTCAATATGCTTGAC-3′
    UPC2seqD 5′-GTTTCCAGTGCTTTTGGACTCTCC-3′
    UPC2seqZ 5′-CCTATCATCTACGCGGTATTGACC-3′
    UPC2seqF 5′-TGGAGGAATCACCGGCTGAG-3′
    UPC2seqG 5′-GTCAAGCATATTGAGATTTGACCG-3′
    UPC2seqH 5′-GGAGAGTCCAAAAGCACTGGAAAC-3′
a

Underlined sequence reflects the introduction of a restriction site sequence.

HHS Vulnerability Disclosure